
ASPREE: aspirin tied to 70% lower dementia with high platelet-count genetic scores
Monash researchers analysed genetic data from 13,541 ASPREE participants and found that among those in the top 20% of a platelet-count polygenic score, 1% on 100 mg aspirin developed dementia versus 3.3% on placebo. Aspirin is not recommended for dementia prevention, and this is a genetic subgroup finding that needs confirmation, with bleeding risk to weigh.
